HK1107026A1 - Treatment of short bowel syndrome patients with colon-in-continuity - Google Patents

Treatment of short bowel syndrome patients with colon-in-continuity

Info

Publication number
HK1107026A1
HK1107026A1 HK08100908.3A HK08100908A HK1107026A1 HK 1107026 A1 HK1107026 A1 HK 1107026A1 HK 08100908 A HK08100908 A HK 08100908A HK 1107026 A1 HK1107026 A1 HK 1107026A1
Authority
HK
Hong Kong
Prior art keywords
colon
continuity
treatment
bowel syndrome
short bowel
Prior art date
Application number
HK08100908.3A
Other languages
English (en)
Inventor
Elizabeth L Sanguinetti
Thomas B Marriott
Jennifer Lopansri
Consuelo Maria Blosch
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36319726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1107026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Publication of HK1107026A1 publication Critical patent/HK1107026A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK08100908.3A 2004-11-01 2008-01-24 Treatment of short bowel syndrome patients with colon-in-continuity HK1107026A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62323304P 2004-11-01 2004-11-01
PCT/US2005/039222 WO2006050244A2 (fr) 2004-11-01 2005-11-01 Traitement de patients atteints du syndrome de l'intestin court avec colon en continuite

Publications (1)

Publication Number Publication Date
HK1107026A1 true HK1107026A1 (en) 2008-03-28

Family

ID=36319726

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100908.3A HK1107026A1 (en) 2004-11-01 2008-01-24 Treatment of short bowel syndrome patients with colon-in-continuity

Country Status (8)

Country Link
US (70) US7847061B2 (fr)
EP (1) EP1809318B1 (fr)
JP (1) JP5197012B2 (fr)
CA (1) CA2585482C (fr)
DK (1) DK1809318T3 (fr)
ES (1) ES2427150T3 (fr)
HK (1) HK1107026A1 (fr)
WO (1) WO2006050244A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DK1809318T3 (da) 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
BRPI0610091B1 (pt) * 2005-05-04 2021-08-03 Zealand Pharma A/S Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
US8642727B2 (en) 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2011143335A2 (fr) * 2010-05-11 2011-11-17 Nps Pharmaceuticals, Inc. Méthodes de traitement ou de prophylaxie d'un dysfonctionnement rénal ou hépatique
EP2844670B1 (fr) 2012-05-03 2017-12-06 Zealand Pharma A/S Analogues du glucagon-like peptide 2 (glp-2)
US20170063005A1 (en) * 2015-08-27 2017-03-02 Tyco Electronics Corporation Array connector and method of manufacturing the same
TWI591177B (zh) 2016-10-27 2017-07-11 中化合成生技股份有限公司 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
DK3551651T3 (da) 2016-12-09 2024-05-13 Zealand Pharma As Acylerede glp-1/glp-2-dobbeltagonister
WO2018142363A1 (fr) * 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Compositions d'analogues de glp-2 prêtes à l'emploi par l'intermédiaire de dispositifs auto-administrables
IL299864B2 (en) * 2017-06-16 2024-06-01 Zealand Pharma As Dosing regimen for glucagon-like peptide (GLP-2) analog administration 2
US10105588B1 (en) 2017-09-26 2018-10-23 Chasen Massey Snowboard binding with adjustment memory
EP3706774A4 (fr) * 2017-11-06 2021-09-08 Shire-NPS Pharmaceuticals, Inc. Analogues de glp-2 et peptibodies destinés à être administrés avant, pendant ou après une intervention chirurgicale
EP3844500A4 (fr) * 2018-08-27 2022-05-11 NantBio, Inc. Compositions de rp182 et procédés
WO2020165900A1 (fr) 2019-02-11 2020-08-20 Opko Biologics Ltd. Analogues de glp-2 à action prolongée
CN116157413A (zh) 2020-06-09 2023-05-23 维克蒂生物股份有限公司 阿普拉鲁肽的制造、配制和给药

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
CA2221136A1 (fr) 1995-06-06 1996-12-12 Kimberly-Clark Worldwide, Inc. Feuil microporeux contenant un adsorbant microbien
DK1231219T3 (da) * 1996-04-12 2010-12-20 Ontario Inc 1149336 GLucagon-lignende peptid-2 analoger
EG21623A (en) 1996-04-16 2001-12-31 Procter & Gamble Mid-chain branced surfactants
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US6077949A (en) 1996-12-13 2000-06-20 Allelix Biopharmaceuticals, Inc. Cloned glucagon-like peptide 2 receptors
PT981362E (pt) 1997-05-16 2004-03-31 Ontario Inc 1149336 Metodos de melhoramento do funcionamento do tracto gastrointestinal superior
AU2712899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
CA2436399A1 (fr) 2001-02-16 2002-08-29 Conjuchem Inc. Peptide 2 de type glucagon (glp-2) de longue duree utilise dans le traitement des maladies et troubles gastro-intestinaux
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
EP1608680A2 (fr) 2003-03-24 2005-12-28 Novo Nordisk A/S Derives de glp-2
DK1809318T3 (da) * 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet

Also Published As

Publication number Publication date
US20200164041A1 (en) 2020-05-28
US20190307852A1 (en) 2019-10-10
US9968657B2 (en) 2018-05-15
US20190275112A1 (en) 2019-09-12
US20170020987A1 (en) 2017-01-26
EP1809318A2 (fr) 2007-07-25
US20210015903A1 (en) 2021-01-21
US20210038695A1 (en) 2021-02-11
US20200405818A1 (en) 2020-12-31
US20170020980A1 (en) 2017-01-26
US20110172152A1 (en) 2011-07-14
US20200376084A1 (en) 2020-12-03
US20200164043A1 (en) 2020-05-28
US9974835B2 (en) 2018-05-22
US20210000923A1 (en) 2021-01-07
US9974837B2 (en) 2018-05-22
US20170020965A1 (en) 2017-01-26
US20190275113A1 (en) 2019-09-12
US20210077586A1 (en) 2021-03-18
US20180264087A1 (en) 2018-09-20
US20190351027A1 (en) 2019-11-21
US20170028026A1 (en) 2017-02-02
US9545434B2 (en) 2017-01-17
DK1809318T3 (da) 2013-09-08
US9968658B2 (en) 2018-05-15
US20200147182A1 (en) 2020-05-14
US9974838B2 (en) 2018-05-22
US20170020984A1 (en) 2017-01-26
US20190262427A1 (en) 2019-08-29
US9545435B1 (en) 2017-01-17
US20170020983A1 (en) 2017-01-26
US20170028030A1 (en) 2017-02-02
US9968655B2 (en) 2018-05-15
US20200390862A1 (en) 2020-12-17
US20190381146A1 (en) 2019-12-19
US20200129593A1 (en) 2020-04-30
US20170020981A1 (en) 2017-01-26
US9993528B2 (en) 2018-06-12
WO2006050244A2 (fr) 2006-05-11
US20170020977A1 (en) 2017-01-26
US9592274B2 (en) 2017-03-14
US20170020986A1 (en) 2017-01-26
US20170020967A1 (en) 2017-01-26
US20200016241A1 (en) 2020-01-16
US20170020969A1 (en) 2017-01-26
US9981016B2 (en) 2018-05-29
US9987335B2 (en) 2018-06-05
US20170020971A1 (en) 2017-01-26
EP1809318B1 (fr) 2013-06-12
US20170028025A1 (en) 2017-02-02
ES2427150T3 (es) 2013-10-29
US9981014B2 (en) 2018-05-29
US20190298806A1 (en) 2019-10-03
US20170020989A1 (en) 2017-01-26
US20170028028A1 (en) 2017-02-02
US20200397866A1 (en) 2020-12-24
US20170020975A1 (en) 2017-01-26
US20210015904A1 (en) 2021-01-21
US20170020970A1 (en) 2017-01-26
US7847061B2 (en) 2010-12-07
JP5197012B2 (ja) 2013-05-15
US9555079B1 (en) 2017-01-31
US20170020988A1 (en) 2017-01-26
US20170020985A1 (en) 2017-01-26
US9968656B2 (en) 2018-05-15
US20200147181A1 (en) 2020-05-14
WO2006050244A3 (fr) 2006-09-08
US20200206316A1 (en) 2020-07-02
US20170020976A1 (en) 2017-01-26
US20170028029A1 (en) 2017-02-02
US20170020968A1 (en) 2017-01-26
US20210213106A1 (en) 2021-07-15
US9539310B1 (en) 2017-01-10
US9999656B2 (en) 2018-06-19
US20200138910A1 (en) 2020-05-07
CA2585482A1 (fr) 2006-05-11
US9974836B2 (en) 2018-05-22
US20200164040A1 (en) 2020-05-28
US20190262428A1 (en) 2019-08-29
US9592273B2 (en) 2017-03-14
US20200376085A1 (en) 2020-12-03
US9987334B2 (en) 2018-06-05
US20200129594A1 (en) 2020-04-30
US20170020978A1 (en) 2017-01-26
US20170028027A1 (en) 2017-02-02
US20170020979A1 (en) 2017-01-26
CA2585482C (fr) 2018-01-02
US20170020982A1 (en) 2017-01-26
US20170020974A1 (en) 2017-01-26
US20190298807A1 (en) 2019-10-03
US20170020972A1 (en) 2017-01-26
US20060135424A1 (en) 2006-06-22
US20190275111A1 (en) 2019-09-12
US20170020966A1 (en) 2017-01-26
US20170020973A1 (en) 2017-01-26
US9572867B2 (en) 2017-02-21
US20170028024A1 (en) 2017-02-02
US9060992B2 (en) 2015-06-23
US9981015B2 (en) 2018-05-29
JP2008518941A (ja) 2008-06-05
US20190269760A1 (en) 2019-09-05
US20210236603A1 (en) 2021-08-05
US20210213105A1 (en) 2021-07-15
US20150290296A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
HK1107026A1 (en) Treatment of short bowel syndrome patients with colon-in-continuity
EP1827338A4 (fr) Traitement de l'incontinence anale
EP1731113A4 (fr) Kit de traitement m dical
EP1755584A4 (fr) Traitement de la myopie
GB0403969D0 (en) Tissue treatment device
EP1738735A4 (fr) Lit médical
EP1789047A4 (fr) Procede pour traiter des maladies au moyen de nalmefene et de ses analogues
IL178827A0 (en) Use of reboxetine for the treatment of pain
EP1755635A4 (fr) Traitement d'affection inflammatoire des voies respiratoires
GB0415181D0 (en) Compounds for use in the treatment of infection
EP1793813A4 (fr) Traitement du trouble d'hyperactivite avec deficit de l'attention (thada)
GB0426196D0 (en) Methods of treatment
EP1767210A4 (fr) Utilisation medicale de paeoniflorine
GB0426141D0 (en) Treatment
GB0701549D0 (en) Skin treatment
GB0425854D0 (en) Therapeutic treatment
GB0423173D0 (en) Treatment of diabetes
IL180709A0 (en) Treatment of tumours
ZA200704046B (en) Treatment of burns
GB0419703D0 (en) Medical treatment
GB0401807D0 (en) Medical treatment
GB0415318D0 (en) Medical treatment
GB0401792D0 (en) Medical treatment
GB0408752D0 (en) Therapeutic treatment
HU0400952D0 (en) Treatment of anus-cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231027